Monash Institute of Pharmaceutical Sciences, Monash University, Melbourne, Victoria, 3052, Australia.
Proteomics. 2019 May;19(10):e1700448. doi: 10.1002/pmic.201700448. Epub 2018 Nov 26.
Early detection and diagnosis of cancer can allow timely medical intervention, which greatly improves chances of survival and enhances quality of life. Biomarkers play an important role in assisting clinicians and health care providers in cancer diagnosis and treatment follow-up. In spite of years of research and the discovery of thousands of candidate cancer biomarkers, only a few have transitioned to routine usage in the clinic. This review highlights advances in proteomics technologies that have enabled high rates of discovery of candidate cancer biomarkers and evaluates integration with other omics technologies to improve their progress through to validation and clinical translation. Furthermore, it gauges the role of metabolomics technology in cancer biomarker research and assesses it as a complementary tool in aiding cancer biomarker discovery and validation.
癌症的早期检测和诊断可以使及时的医疗干预成为可能，这大大提高了生存机会并提高了生活质量。生物标志物在协助临床医生和医疗保健提供者进行癌症诊断和治疗随访方面发挥着重要作用。尽管经过多年的研究和发现了数千种候选癌症生物标志物，但只有少数几种已转化为临床常规使用。这篇综述强调了蛋白质组学技术的进步，这些技术使候选癌症生物标志物的发现率大大提高，并评估了与其他组学技术的整合，以改善其通过验证和临床转化的进展。此外，它还评估了代谢组学技术在癌症生物标志物研究中的作用，并将其评估为辅助癌症生物标志物发现和验证的一种补充工具。
